News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CV Technologies Inc. (CC:CVQ) Release: World's Top Cancer Research Body Sponsors Landmark COLD-FX(R) Trial


11/17/2008 11:46:49 AM

EDMONTON, ALBERTA--(Marketwire - November 17, 2008) - CV Technologies Inc. (TSX: CVQ) today announced that COLD-FX® will be the focus of a landmark U.S. National Cancer Institute (NCI) sponsored trial involving chronic lymphocytic leukemia patients - the first time the natural medicine will be part of a clinical study associated with cancer. The NCI, part of the U.S. National Institutes of Health, is the world's most prestigious cancer research body. The trial will be conducted by American cancer and infectious diseases experts at Wake Forest University School of Medicine in Winston-Salem, North Carolina.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES